Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.48 |
| ▸ | CCR5 | P51681 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203694 | 0.93 | RORC (0.50) | RORCCCR5SIGMAR1DPP4GBA1 | |
| SCHEMBL3646955 | 0.88 | RORC (0.48) | RORCCCR5SIGMAR1DPP4GBA1 | |
| SCHEMBL3245751 | 0.88 | RORC (0.50) | RORCCCR5SIGMAR1DPP4GBA1 | |
| SCHEMBL3255060 | 0.88 | RORC (0.50) | RORCCCR5SIGMAR1DPP4GBA1 | |
| SCHEMBL3245752 | 0.88 | RORC (0.50) | RORCCCR5SIGMAR1DPP4GBA1 | |
| SCHEMBL1974849 | 0.88 | RORC (0.52) | RORCCCR5SIGMAR1DPP4GBA1 | |
| SCHEMBL7878252 | 0.88 | RORC (0.52) | RORCCCR5SIGMAR1DPP4GBA1 | |
| SCHEMBL1976030 | 0.88 | RORC (0.52) | RORCCCR5SIGMAR1DPP4GBA1 | |
| SCHEMBL1421644 | 0.88 | RORC (0.52) | RORCCCR5SIGMAR1DPP4GBA1 | |
| SCHEMBL13198817 | 0.88 | RORC (0.52) | RORCCCR5SIGMAR1DPP4GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398768-B1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-8318759-B2 | Pyrrolidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | RORC 1018/4885CCR5 1616/4885SIGMAR1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.